Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component (Q39750078)

14 September 2017

Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component (English)

1 reference

14 September 2017

Renske A de Jong

1

1 reference

14 September 2017

Hans W Nijman

2

1 reference

14 September 2017

Tera F Wijbrandi

3

1 reference

14 September 2017

Anna Kl Reyners

4

1 reference

14 September 2017

H Marike Boezen

5

1 reference

14 September 2017

Harry Hollema

6

1 reference

14 September 2017

13 May 2011

1 reference

14 September 2017

1 reference

14 September 2017

24

1 reference

14 September 2017

10

1 reference

14 September 2017

1368-1379

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.88

14 September 2017

0 references

cites work

Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Two pathogenetic types of endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Uterine sarcomas: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Tissue microarrays for high-throughput molecular profiling of tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

DNA mismatch repair deficiency in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Microsatellite instability in uterine sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

PTEN mutations in uterine sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

Molecular profiling of endometrial malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Microsatellite instability in endometrial carcinomas: clinicopathologic correlations in a series of 42 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

Nuclear beta-catenin in mesenchymal tumors

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.88

7 January 2021

10.1038/MODPATHOL.2011.88

Identifiers

DOI

1 reference

Dimensions Publication ID

14 September 2017

0 references

1 reference